An interventional study of Image-Based Counseling and Smoking Cessation Coaching in Lung Cancer (Diagnosis), Smoking Cessation and Lung Neoplasm, sponsored by Hôpital Fribourgeois. Not yet recruiting at 1 site in Switzerland. Open to participants aged 50 Years to 79 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-10-21.
Sponsored by Hôpital Fribourgeois · Not applicable, Interventional, and Prevention
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 98 studies in Lung Neoplasms with a site in Switzerland — 26 open to participants now, 32 under way, 11 of them phase 3. Lung Neoplasms · Switzerland.
Among the 98 studies in Lung Neoplasms with a site in Switzerland, this one is the 41st largest by planned enrollment of the 77 interventional ones that give a count, is the only one that started in 2027, is one of 13 with no phase, reaches primary completion later than 29 of the 31 other live ones, and was the 98th registered.
5,436 studies on the registry are indexed under Lung Neoplasms; 1,350 are open to participants now.
Browse Lung Neoplasms studies →26 of the 98 studies in Lung Neoplasms with a site in Switzerland are open now. Recruiting first, the newest first:
Intuitive Surgical · Sites in Switzerland, Germany, United Kingdom
Ages 18+
Oncology Institute of Southern Switzerland · Sites in Switzerland
Ages 18+
Oncology Institute of Southern Switzerland · Sites in Switzerland
Ages 18+
Bristol-Myers Squibb · Sites in Switzerland, United States, Argentina and 22 more countries
Ages 18+
Hoffmann-La Roche · Sites in Switzerland, United States, Argentina and 25 more countries
Ages 18+
A study can be open while its sites in Switzerland have not opened yet or have stopped. Only those recruiting at a site in Switzerland →
Of the 997 Lung Neoplasms studies recruiting now, 686 (69%) set no upper age limit and 143 (14%) stop at 75 or younger; 45 take children under 18; 143 take healthy volunteers.
This study: 50 Years to 79 Years · all sexes · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
98 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 8 · Phase 2 25 · Phase 3 31 · Phase 4 5
First in 1995; this study’s year is marked. 1 started in 2027.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 116 is above the median of 60 across 3,668 interventional studies indexed under Lung Neoplasms.
Median enrollment 136 across the 77 interventional studies, 294 across the 20 observational. Of the 61 that completed or were terminated, 18 (30%) have results posted.
This tab as a report to print or save as PDF → With an account.
40 of 98 have an industry lead sponsor. The 10 most frequent:
Hôpital Fribourgeois is the lead sponsor of 18 studies on the registry; 12 are open to participants now.
Hôpital Fribourgeois has 1 study filed under Lung Neoplasms — fewer than ten, so there is no comparison to draw.
6 of the studies in Lung Neoplasms with a site in Switzerland that are under way reach primary completion within a year, 3 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05920356Phase 3AmgenA Study Evaluating Sotorasib Platinum Doublet Combination Versus Pembrolizumab Platinum Doublet Combination as a Front-Line Therapy in Participants With Stage IV or Advanced Stage IIIB/C Nonsquamous Non-Small Cell Lung Cancers (CodeBreaK 202) | 2027-06-30 |
| NCT06119581Phase 3Eli Lilly and CompanyA Study of First-Line Olomorasib (LY3537982) and Pembrolizumab With or Without Chemotherapy in Patients With Advanced KRAS G12C-Mutant Non-small Cell Lung Cancer | 2027-11 |
| NCT07099898Phase 3GlaxoSmithKlineA Study of GSK5764227 in Participants With Relapsed Small Cell Lung Cancer (SCLC) [EMBOLD SCLC-301] | 2027-11-05 |
| NCT03979170University Hospital, GenevaPatient-derived Organoids of Lung Cancer to Test Drug Response | 2026-12-30 |
| NCT07398027Carolin SteinackPost-Market Study of Transbronchial Cryo-assisted RFA During Robotic Bronchoscopy With Subsequent Surgical Resection | 2027-03 |
Add all 6 to your calendar (.ics) → With an account.
Among the 98 studies in Lung Neoplasms with a site in Switzerland, from their registry updates:
This tab as a report to print or save as PDF → With an account.
Lung cancer is common and serious, but when detected early, the chances of recovery are significantly better. Tobacco use is the leading cause. To help people break free from smoking, the Fribourg Cantonal Hospital (HFR), the Center for Tobacco Prevention (CIPRET), and the Fribourg Cancer League are joining forces in the STOP-LungCancer study (Smoking Termination Outcomes with Pulmonary Low Dose Computed Tomography for Lung Cancer Screening).
What is the goal of this study? The investigators want to determine whether seeing and understanding images of the participants' own lungs helps participants quit smoking for good. Smoking cessation will be verified at 6 months using a breath test (measuring carbon monoxide), followed by a 2-year follow-up.
How does participation work? The study is open to 116 residents of the canton of Fribourg aged 50 to 79 who are heavy smokers and motivated to quit.
The program includes:
What are the benefits? Participants receive both tailored support to quit smoking and close monitoring to detect any potential issues at a very early stage.
The criteria were revised on the registry on Oct 7, 2026. See what changed
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
ECOG performance status
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Single-arm experimental cohort of heavy smokers undergoing an integrated lung cancer screening and smoking cessation pathway. All enrolled participants receive the combined intervention strategy, which pairs personalized chest computed tomography (CT) imaging results with dedicated specialist counseling and structured behavioral smoking cessation support. This arm aims to evaluate how visual radiological feedback combined with tobacco cessation counseling impacts long-term smoking abstinence rates.
Behavioral: Image-Based Counseling · Behavioral: Smoking Cessation Coaching · Radiation: Low-Dose Chest Computed Tomography (LDCT)
Face-to-face physician consultations where a thoracic radiologist reviews the participant's own computed tomography (CT) scans with the participant to explain lung and cardiovascular health, creating a visual "teachable moment".
Four structured behavioral counseling sessions delivered by certified tobacco cessation experts of the Center for Tobacco Prevention (CIPRET), personalized to support long-term abstinence.
Also known as: Smoking Cessation Counselling
Low-dose chest computed tomography (LDCT) scans without intravenous contrast at baseline, 12 months, and 24 months, and additional follow-up LDCT when indicated by the screening result (Lung Computed Tomography Screening Reporting and Data System \[Lung-RADS\] category 3).
Also known as: lung cancer screening (LCS)
6-Month Smoking Abstinence Rate
Proportion of participants who achieve smoking abstinence at 6 months after the first chest computed tomography (CT). Abstinence is self-reported and objectively validated using exhaled carbon monoxide (CO) measurement.
Time frame: 6 months after the first chest computed tomography (CT)
Smoking Abstinence Rate at 12 Months
Proportion of participants reporting smoking abstinence at the 12-month visit, confirmed by exhaled carbon monoxide (CO) measurement.
Time frame: 12 months after the first chest computed tomography
Smoking Abstinence Rate at 24 Months
Proportion of participants reporting smoking abstinence at the 24-month visit, confirmed by exhaled carbon monoxide (CO) measurement.
Time frame: 24 months after the first chest computed tomography
Detection Rate of Lung Nodules and Lung Cancer
Proportion of participants with positive low-dose computed tomography (LDCT) findings requiring further diagnostic follow-up or tissue biopsy, categorized according to the standardized Lung Computed Tomography Screening Reporting and Data System (Lung-RADS) assessment categories.
Time frame: Baseline, 12 months, and 24 months
Prevalence of Relevant Incidental Findings on Chest Computed Tomography
Proportion of relevant non-lung-nodule incidental findings detected on low-dose chest computed tomography, such as smoking-related lung disease, cardiac abnormalities and other findings unrelated to smoking.
Time frame: Baseline, 12 months, and 24 months
Factors Potentially Influencing Smoking Cessation Success
Exploratory analysis evaluating demographics such as age, sex, place of residence, socioeconomical class, and other factors such as smoking-related lung disease, and cardiac abnormalities. These analyses are exploratory in nature and are intended to generate hypotheses for future studies. No definitive causal inference will be drawn from these analyses.
Time frame: At baseline
Plan to share: No — Individual participant data will not be made publicly available to protect participant privacy and maintain confidentiality in accordance with Swiss regulatory requirements (Human Research Act and Federal Act on Data Protection). Aggregated data and primary results will be available in peer-reviewed scientific publications.
No publications or documents are linked to this record.
Start is estimated for Jan 2027; primary completion for Jun 2031, 53 months later.
Of 871 non-industry interventional studies with no phase under Lung Neoplasms, half reached primary completion within 35 months of starting (the median), counting those still running; a quarter within 16 and three quarters within 69. This study's planned 53 months is above that.
Counting every sponsor, half of 922 studies reached it within 34 months; a quarter within 15 and three quarters within 67.
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is not yet recruiting, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Hôpital Fribourgeois